# A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer

Source: https://onco.cc/trials/nct06474468/  
OnCo record `nct06474468` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Adebrelimab, Cisplatin and SHR-A2102 in oesophageal cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer is a phase 1/2 interventional study registered as NCT06474468 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 148 participants planned, started 2024-06-20 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A2102；Adebrelimab；Cisplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06474468
- Phase: 1/2
- Setting: A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 148

## Sources

- ClinicalTrials.gov NCT06474468: https://clinicaltrials.gov/study/NCT06474468

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06474468.json